NICE questions cost-effectiveness for Adtralza, Rinvoq and Cibinqo
The National Institute for Health and Care Excellence (NICE) does not recommend the agents for the treatment of atopic dermatitis.
By
Immunology
Latest in
Immunology
Pipeline therapies promising better disease management for osteoarthritis
GlobalData has identified drug candidates for osteoarthritis that could shift the competitive landscape and treatment paradigm.
By
Sanofi and IGM partner to develop IgM antibody agonists for six targets
Sanofi will make more than $6bn in development, regulatory, and commercial milestone payments to IGM.
Bacteria and balance: how understanding the vaginal microbiome can help discover new drugs
Imbalance in the vaginal microbiome has been linked to a range of conditions, from UTIs to preterm birth.
By
Pfizer concludes Arena Pharmaceuticals acquisition for $6.7bn
Pfizer will gain access to Arena’s portfolio of various treatment candidates for gastroenterology, dermatology and cardiology.
With Staquis’ exit, PDE-4 class potential in AD is uncertain
Pfizer’s Staquis and other PDE4 therapies for atopic dermatitis may soon be outpaced by treatments with other methods of action.
By
AstraZeneca’s Saphnelo gets approval in the EU for SLE
The approval is based on data from the clinical development programme of Saphnelo, including the TULIP and MUSE trials.
China grants approval to GSK’s Benlysta for lupus nephritis treatment
The approval is based on findings from the Phase III BLISS-LN clinical trial of belimumab in adults with active LN.